Recombinant Human Bifunctional Epoxide Hydrolase 2 (EPHX2) Protein (His-SUMO)

Name: Recombinant Human Bifunctional Epoxide Hydrolase 2 (EPHX2) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-10825P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Bifunctional Epoxide Hydrolase 2 (EPHX2) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P34913
Target Symbol	EPHX2
Synonyms	Bifunctional epoxide hydrolase 2; CEH; Cytosolic epoxide hydrolase; EPHX2; Epoxide hydratase; Epoxide hydrolase 2; Epoxide hydrolase 2 cytoplasmic; epoxide hydrolase 2, cytosolic; Epoxide hydrolase soluble; HYES_HUMAN; SEH; Soluble epoxide hydrolase
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	MTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARNPPVVSKM
Expression Range	1-555aa
Protein Length	Full Length
Mol. Weight	78.6kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. Plays a role in xenobiotic metabolism by degrading potentially toxic epoxides. Also determines steady-state levels of physiological mediators.; Bifunctional enzyme. The N-terminal domain has lipid phosphatase activity, with the highest activity towards threo-9,10-phosphonooxy-hydroxy-octadecanoic acid, followed by erythro-9,10-phosphonooxy-hydroxy-octadecanoic acid, 12-phosphonooxy-octadec-9Z-enoic acid and 12-phosphonooxy-octadec-9E-enoic acid. Has phosphatase activity toward lyso-glycerophospholipids with also some lower activity toward lysolipids of sphingolipid and isoprenoid phosphates.
Subcellular Location	Cytoplasm. Peroxisome.
Protein Families	AB hydrolase superfamily, Epoxide hydrolase family
Database References	HGNC: 3402 OMIM: 132811 KEGG: hsa:2053 STRING: 9606.ENSP00000430269 UniGene: PMID: 29629376 Single nucleotide polymorphism of EPHX2 rs751141 is associated with Early Neurological Deterioration. PMID: 28835580 The activity of Ephx2 promoter-coding luciferase was significantly attenuated in HEK293T cells treated with 17beta-E2. PMID: 29295935 hypomethylation of the promoter region of EPHX2 and K55R polymorphism were associated with significant increased risk of pre-eclampsia. PMID: 29058492 Study demonstrated an isolated gene change, sEH R287Q, in a core family of familial hypercholesterolemia (FH). The results showed that sEH R287Q decreased the expression level and hydrolase activity of sEH, decreased the binding of LDL to LDLR and LDL internalization in cultured hepatocyte cell line BEL-7402. PMID: 29665449 Soluble epoxide hydrolase plays role in the choroidal neovascularization PMID: 29193961 Interestingly, rs2279590 locus has a widespread enhancer effect on two nearby genes, protein tyrosine kinase 2 beta (PTK2B) and epoxide hydrolase-2 (EPHX2); both of which have been previously associated with AD as risk factors. PMID: 28973302 Results showed that among type 2 diabetic patients, the combined effect of MTHFR TT and EPHX2 GG or GA + AA genotype has a higher risk of ischemic stroke compared with the control group. PMID: 28409162 we describe the bacterial expression of the recombinant N-terminal domain of sEH-P and the development of a high-throughput screening protocol using a sensitive and commercially available substrate fluorescein diphosphate. The usability of the assay system was demonstrated and novel inhibitors of sEH-P were identified. PMID: 27009944 The WT sEH formed a very tight dimer, with a KD/M in the low picomolar range. Only R287Q resulted in a large change of the KD/M However, human tissue concentrations of sEH suggest that it is always in its dimer form independently of the SNP. PMID: 24771868 The EPHX2 Lys55Arg polymorphism is associated with AKI following cardiac surgery in patients without preexisting CKD PMID: 28552948 EPHX2 polymorphism , might be important determinant of hydrochlorothiazide treatment in patients with hypertension. PMID: 27381900 This study meta-analysis results did not show significant associations between the polymorphisms of EPHX2. PMID: 27266621 EPHX2 Variants are associated with Ischemic Stroke. PMID: 27087514 Because Epoxide Hydrolase 2 (EPHX2) was identified as a novel AN susceptibility gene, and because its protein product, soluble epoxide hydrolase (sEH), converts bioactive epoxides of polyunsaturated fatty acid (PUFA) to the corresponding diols, lipidomic and metabolomic targets of EPHX2 were assessed to evaluate the biological functions of EPHX2 and their role in AN. PMID: 25824304 Increased levels of soluble epoxide hydrolase in the brain of depressed patients PMID: 26976569 carriers of rs1042032 GG genotype had lower estimated glomerular filtration rate and higher serum creatinine values 1 year after grafting compared to patients carrying wildtype A-allele; this GG genotype also associated to increased risk of acute rejection; results suggest genetic variability in EPHX2 may have an impact on outcome of deceased-donor renal transplantation PMID: 26230946 Suggest role for Ephx2 in vascular smooth muscle phenotypic modulation and migration in the development of atherosclerosis. PMID: 26453326 Essential hypertension is associated with the rs751141 G/A allele gene polymorphism in EPHX2 in Han subjects but not in Kazakh and Uygur subjects. PMID: 25966114 Within the EPHX2 promoter -56/+32, five Sp1-binding sites were identified, and the mutation of each of these sites showed that the first one (SP1_1) was important in both suppression by Sp1 and activation by AP2alpha. PMID: 26341485 A genetic variant that results in decreased soluble epoxide hydrolase activity is associated with increased insulin sensitivity. PMID: 25173047 Potent natural soluble epoxide hydrolase inhibitors from Pentadiplandra brazzeana baillon: synthesis, quantification, and measurement of biological activities in vitro and in vivo. PMID: 25659109 Genetic polymorphisms of soluble EH are associated with neurological and vital outcomes after aneurysmal subarachnoid hemorrhage. PMID: 25216066 Findings suggest a novel association of gene variants within EPHX2 to susceptibility to anorexia nervosa and provide a foundation for future study of this important yet poorly understood condition PMID: 23999524 Presence of single nucleotide polymorphism rs751141 of EPHX2 is associated with significantly increased risk of atrial fibrillation recurrence following catheter ablation. PMID: 23711456 Evidence suggests that modulation of plasma levels of epoxyeicosatrienoic acid (EET) (for example, down-regulation of EET in patients with renovascular disease-associated hypertension) is due, in part, to up-regulation of EPHX2. [REVIEW] PMID: 23011468 sEH is a physiological modulator of ER stress and a potential target for mitigating complications associated with obesity PMID: 23576437 the importance of sEH in MCP-1-regulated monocyte chemotaxis PMID: 23160182 Soluble epoxide hydrolase dimerization is required for hydrolase activity PMID: 23362272 The essential hypertension in Kazaks in Xinjiang is not associated with rs751141G/A gene polymorphism, but is associated with rs751141G/A allele gene polymorphism of EPHX2. PMID: 22336502 Upregulation of sEH in proximal tubular cells in chronic proteinuric kidney diseases may mediate proteinuria-induced renal damage. PMID: 23152298 investigation of role of cytoplasmic Ephx2 in diabetic nephropathy by gene disruption techniques: Ephx2 gene inhibition (or added epoxyeicosatrienoic acids) protects renal proximal tubular cell line from tumor necrosis factor-alpha-induced apoptosis. PMID: 22739108 sEH is one of the etiological factors of cardiovascular diseases, and plays an important role in the progression of myocardium ischemia. PMID: 21704394 ATF6 activation and DNA demethylation may coordinately contribute to Hcy-induced sEH expression and endothelial activation. PMID: 22354938 These findings also underline possible cellular mechanisms by which both activities of sEH (EH and phosphatase) may have complementary or opposite roles. PMID: 22387545 This case-control study as well as meta-analysis suggested no association between CYP2J2 G-50T and EPHX2 R287Q and the risk of developing coronary artery disease . PMID: 21642892 In patients with IgA nephropathy, some single nucleotide polymorphisms of EPHX2 were associated with more rapid disease progression. PMID: 21429967 The PLA2G7, HPGD, EPHX2, and CYP4F8 genes are highly expressed in prostate cancer. PMID: 21281786 SP-1 is involved in the decrease in the transcription of sEH as a result of DNA methylation in HepG2 cells, which might contribute to epigenetic mechanism-induced carcinogenesis in hepatocytes. PMID: 20888937 Genetic variation in epoxide hydrolase 2 is associated with forearm vasodilator responses in a bradykinin receptor- and endothelium-independent manner, suggesting an important role for soluble epoxide hydrolase in regulating vascular function in humans. PMID: 21098312 The functional K55R polymorphism of the EPHX2 gene confers a higher risk of hypertension prevalence and increases the risk of incident ischemic stroke in male homozygotes. PMID: 20065888 Results show that no relationship exists between EPHX2 and risk of ischemic stroke, myocardial infarction, and ischemic heart disease. PMID: 19940276 Common polymorphisms within EPHX2 do not appear to be important risk factors for Parkinson's disease. PMID: 11692079 Close association of soluble epoxide hydrolase gene G860A (Arg287Gln) polymorphism with insulin resistance in type 2 diabetic patients. PMID: 15845398 Multiple variants exist within or near the EPHX2 gene, with greatly contrasting relationships to ischemic stroke incidence; some associated with a higher incidence and others with a lower incidence. PMID: 16115816 Soluble epoxide epoxygenase-related SNP is not associated with increased risk of hypertension in the African American population. PMID: 16202848 Consistent with the finding of isoprenoid phosphates as substrates for sEH, we identified isoprenoid-derived N-terminal inhibitors with IC50 values ranging from 0.84 (+/-0.9) to 55.1 (+/-30.7) microM. PMID: 16414022 EPHX2 has an emerging role as a risk factor for atherosclerosis, whose effects are influenced by smoking PMID: 16545818 EPHX2 as a potential cardiovascular disease-susceptibility gene. PMID: 16595607 human EPHX2 mutations may in part explain the genetic variability in sensitivity to ischemic brain injury and stroke outcome PMID: 17460077

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.